Synthesis, In Vitro α-Amylase Activity, and Molecular Docking
			Study of New Benzimidazole Derivatives

Ullah, Hayat; Ullah, Hafeez; Taha, Muhammad; Khan, Fahad; Uddin, Imad; Sarfraz, Maliha; Aziz, Aamir; Mubeen, Sidra

doi:10.1134/s1070428021060130

Cited by 30 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our research group had identified several heterocyclic compounds as potent therapeutics [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] and previously published thiazole and sulfonamide derivatives with Sulfonamide-containing compounds have received substantial attention in the last few decades and have emerged as potent inhibitors against various diseases, including diabetes [23], psychosis [24], central nervous system (CNS) disorders [25], tumors [26], and different cancer treatments [27].…”

Section: Introductionmentioning

confidence: 99%

“…Our research group had identified several heterocyclic compounds as potent therapeutics [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ] and previously published thiazole and sulfonamide derivatives with various biological potentials [ 43 , 44 , 45 , 46 ] (see Figure 2 ). Keeping in view the biological importance of thiazole and sulfonamide derivatives, we have planned to design and synthesize a new hybrid class of thiazole-based sulfonamide analogs as acetylcholinesterase and butyrylcholinesterase inhibitors in search of lead candidates.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis, DFT Studies, Molecular Docking and Biological Activity Evaluation of Thiazole-Sulfonamide Derivatives as Potent Alzheimer’s Inhibitors

et al. 2023

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease is a major public brain condition that has resulted in many deaths, as revealed by the World Health Organization (WHO). Conventional Alzheimer’s treatments such as chemotherapy, surgery, and radiotherapy are not very effective and are usually associated with several adverse effects. Therefore, it is necessary to find a new therapeutic approach that completely treats Alzheimer’s disease without many side effects. In this research project, we report the synthesis and biological activities of some new thiazole-bearing sulfonamide analogs (1–21) as potent anti-Alzheimer’s agents. Suitable characterization techniques were employed, and the density functional theory (DFT) computational approach, as well as in-silico molecular modeling, has been employed to assess the electronic properties and anti-Alzheimer’s potency of the analogs. All analogs exhibited a varied degree of inhibitory potential, but analog 1 was found to have excellent potency (IC50 = 0.10 ± 0.05µM for AChE) and (IC50 = 0.20 ± 0.050 µM for BuChE) as compared to the reference drug donepezil (IC50 = 2.16 ± 0.12 µM and 4.5 ± 0.11 µM). The structure-activity relationship was established, and it mainly depends upon the nature, position, number, and electron-donating/-withdrawing effects of the substituent/s on the phenyl rings.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Synthesis, DFT Studies, Molecular Docking and Biological Activity Evaluation of Thiazole-Sulfonamide Derivatives as Potent Alzheimer’s Inhibitors

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, some benzimidazole derivatives are well recognized for their antidiabetic potential, especially as potent α-glucosidase and α-amylase inhibitors. A multitude of benzimidazole derivatives were reviewed as α-amylase inhibitors including benzimidazole bearing sulfonamide [ 34 ], 2-arylbenzimidazole [ 35 ], 2-mercaptobenzimidazole [ 36 ], 2-aminobenzimidazole derivatives [ 37 ], substituted benzimidazole analogs [ 38 ], 2-(2-methyl-5-nitro-1 H -imidazol-1-yl)ethylaryl ether [ 39 ], and benzimidazole-based Cu (II)/Zn (II) complexes [ 40 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity

et al. 2023

View full text Add to dashboard Cite

A novel series of benzimidazole ureas 3a–h were elaborated using 2-(1H-benzoimidazol-2-yl) aniline 1 and the appropriate isocyanates 2a–h. The antioxidant and possible antidiabetic activities of the target benzimidazole-ureas 3a–h were evaluated. Almost all compounds 3a–h displayed strong to moderate antioxidant activities. When tested using the three antioxidant techniques, TAC, FRAP, and MCA, compounds 3b and 3c exhibited marked activity. The most active antioxidant compound in this family was compound 3g, which had excellent activity using four different methods: TAC, FRAP, DPPH-SA, and MCA. In vitro antidiabetic assays against α-amylase and α-glucosidase enzymes revealed that the majority of the compounds tested had good to moderate activity. The most favorable results were obtained with compounds 3c, 3e, and 3g, and analysis revealed that compounds 3c (IC50 = 18.65 ± 0.23 μM), 3e (IC50 = 20.7 ± 0.06 μM), and 3g (IC50 = 22.33 ± 0.12 μM) had good α-amylase inhibitory potential comparable to standard acarbose (IC50 = 14.21 ± 0.06 μM). Furthermore, the inhibitory effect of 3c (IC50 = 17.47 ± 0.03 μM), 3e (IC50 = 21.97 ± 0.19 μM), and 3g (IC50 = 23.01 ± 0.12 μM) on α-glucosidase was also comparable to acarbose (IC50 = 15.41 ± 0.32 μM). According to in silico molecular docking studies, compounds 3a–h had considerable affinity for the active sites of human lysosomal acid α-glucosidase (HLAG) and pancreatic α-amylase (HPA), indicating that the majority of the examined compounds had potential anti-hyperglycemic action.

show abstract

“…Benzimidazole is a fused heterocyclic compound formed by the fusion of benzene and imidazole which shows a variety of biological activities such as anti-tumor [ 10 ], anti-glycation [ 11 ], antiprotozoal [ 12 ], anti-diabetic [ 13 ], anti-psychotic [ 14 ], anti-oxidant [ 15 ], and anti-viral [ 16 ]. Some anticancer medicines based on benzimidazole skeletons, such as Bendamustin [ 17 ], Hoechst 33258 [ 18 ], and Nocodazole [ 19 ], are in preclinical or clinical trials ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Benzimidazole Bearing Thiosemicarbazone Derivatives Act as Potent α-Amylase and α-Glucosidase Inhibitors; Synthesis, Bioactivity Screening and Molecular Docking Study

et al. 2022

View full text Add to dashboard Cite

Diabetes mellitus is one of the most chronic metabolic diseases. In the past few years, our research group has synthesized and evaluated libraries of heterocyclic analogs against α-glucosidase and α-amylase enzymes and found encouraging results. The current study comprises the evaluation of benzimidazole-bearing thiosemicarbazone as antidiabetic agents. A library of fifteen derivatives (7–21) was synthesized, characterized via different spectroscopic techniques such as HREI-MS, NMR, and screened against α-glucosidase and α-amylase enzymes. All derivatives exhibited excellent to good biological inhibitory potentials. Derivatives 19 (IC50 = 1.30 ± 0.20 µM and 1.20 ± 0.20 µM) and 20 (IC50 = 1.60 ± 0.20 µM and 1.10 ± 0.01 µM) were found to be the most potent among the series when compared with standard drug acarbose (IC50 = 11.29 ± 0.07 and 11.12 ± 0.15 µM, respectively). These derivatives may potentially serve as the lead candidates for the development of new therapeutic representatives. The structure–activity relationship was carried out for all molecules which are mainly based upon the pattern of substituent/s on phenyl rings. Moreover, in silico docking studies were carried out to investigate the active binding mode of selected derivatives with the target enzymes.

show abstract

Synthesis, In Vitro α-Amylase Activity, and Molecular Docking Study of New Benzimidazole Derivatives

Cited by 30 publications

References 42 publications

Synthesis, DFT Studies, Molecular Docking and Biological Activity Evaluation of Thiazole-Sulfonamide Derivatives as Potent Alzheimer’s Inhibitors

Synthesis, DFT Studies, Molecular Docking and Biological Activity Evaluation of Thiazole-Sulfonamide Derivatives as Potent Alzheimer’s Inhibitors

Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity

Benzimidazole Bearing Thiosemicarbazone Derivatives Act as Potent α-Amylase and α-Glucosidase Inhibitors; Synthesis, Bioactivity Screening and Molecular Docking Study

Contact Info

Product

Resources

About